ADAMTS13 Phenotype in Plasma from Normal Individuals and Patients with Thrombotic Thrombocytopenic Purpura

Overview

Journal Eur J Pediatr

Specialty Pediatrics

Date 2006 Dec 26

PMID 17187257

Citations 13

Authors

Minola Manea

Anncharlotte Kristoffersson

Han-Mou Tsai

Wenhua Zhou

Ingemar Winqvist

Goran Oldaeus

Rolf Billstrom

Peter Bjork

Lars Holmberg

Diana Karpman

Affiliations

Soon will be listed here.

Abstract

The activity of ADAMTS13, the von Willebrand factor cleaving protease, is deficient in patients with thrombotic thrombocytopenic purpura (TTP). In the present study, the phenotype of ADAMTS13 in TTP and in normal plasma was demonstrated by immunoblotting. Normal plasma (n = 20) revealed a single band at 190 kD under reducing conditions using a polyclonal antibody, and a single band at 150 kD under non-reducing conditions using a monoclonal antibody. ADAMTS13 was not detected in the plasma from patients with congenital TTP (n = 5) by either antibody, whereas patients with acquired TTP (n = 2) presented the normal phenotype. Following immunoadsorption of immunoglobulins, the ADAMTS13 band was removed from the plasma of the patients with acquired TTP, but not from that of normal individuals. This indicates that ADAMTS13 is complexed with immunoglobulin in these patients. The lack of ADAMTS13 expression in the plasma from patients with hereditary TTP may indicate defective synthesis, impaired cellular secretion, or enhanced degradation in the circulation. This study differentiated between normal and TTP plasma, as well as between congenital and acquired TTP. This method may, therefore, be used as a complement in the diagnosis of TTP.

Citing Articles

Red blood cell-derived arginase release in hemolytic uremic syndrome.

Friberg N, Arvidsson I, Tontanahal A, Kristoffersson A, Gram M, Kaplan B J Transl Med. 2024; 22(1):17.

PMID: 38178089 PMC: 10765883. DOI: 10.1186/s12967-023-04824-x.

Biological variations of ADAMTS13 and von Willebrand factor in human adults.

Kilercik M, Coskun A, Serteser M, Inan D, Unsal I Biochem Med (Zagreb). 2014; 24(1):138-45.

PMID: 24627722 PMC: 3936977. DOI: 10.11613/BM.2014.015.

Proteolytic processing of von Willebrand factor by adamts13 and leukocyte proteases.

Lancellotti S, Basso M, De Cristofaro R Mediterr J Hematol Infect Dis. 2013; 5(1):e2013058.

PMID: 24106608 PMC: 3787661. DOI: 10.4084/MJHID.2013.058.

Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy.

Tati R, Kristoffersson A, Stahl A, Rebetz J, Wang L, Licht C J Immunol. 2013; 191(5):2184-93.

PMID: 23878316 PMC: 3750088. DOI: 10.4049/jimmunol.1301221.

ADAMTS13 and Von Willebrand factor in patients undergoing hemodialysis.

Rios D, Carvalho M, Figueiredo R, Ferreira C, Rodrigues V, Souza R J Thromb Thrombolysis. 2012; 34(1):73-8.

PMID: 22298244 DOI: 10.1007/s11239-012-0682-1.

References

Karpman D, Holmberg L, Jirgard L, Lethagen S . Increased platelet retention in familial recurrent thrombotic thrombocytopenic purpura. Kidney Int. 1996; 49(1):190-9. DOI: 10.1038/ki.1996.26. View

Tsai H . Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood. 1996; 87(10):4235-44. View

Furlan M, Robles R, Solenthaler M, Lammle B . Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood. 1998; 91(8):2839-46. View

Tsai H, Lian E . Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998; 339(22):1585-94. PMC: 3159001. DOI: 10.1056/NEJM199811263392203. View

Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T . FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005; 129(1):93-100. DOI: 10.1111/j.1365-2141.2005.05420.x. View

Uemura M, Tatsumi K, Matsumoto M, Fujimoto M, Matsuyama T, Ishikawa M . Localization of ADAMTS13 to the stellate cells of human liver. Blood. 2005; 106(3):922-4. DOI: 10.1182/blood-2005-01-0152. View

Rieger M, Mannucci P, Kremer Hovinga J, Herzog A, Gerstenbauer G, Konetschny C . ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood. 2005; 106(4):1262-7. DOI: 10.1182/blood-2004-11-4490. View

Sadler J . von Willebrand factor: two sides of a coin. J Thromb Haemost. 2005; 3(8):1702-9. DOI: 10.1111/j.1538-7836.2005.01369.x. View

Ono T, Mimuro J, Madoiwa S, Soejima K, Kashiwakura Y, Ishiwata A . Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood. 2005; 107(2):528-34. DOI: 10.1182/blood-2005-03-1087. View

10.

Wu J, Fujikawa K, Lian E, McMullen B, Kulman J, Chung D . A rapid enzyme-linked assay for ADAMTS-13. J Thromb Haemost. 2006; 4(1):129-36. DOI: 10.1111/j.1538-7836.2005.01677.x. View

11.

Jin M, Cataland S, Bissell M, Wu H . A rapid test for the diagnosis of thrombotic thrombocytopenic purpura using surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF)-mass spectrometry. J Thromb Haemost. 2006; 4(2):333-8. DOI: 10.1111/j.1538-7836.2006.01758.x. View

12.

Soejima K, Nakamura H, Hirashima M, Morikawa W, Nozaki C, Nakagaki T . Analysis on the molecular species and concentration of circulating ADAMTS13 in Blood. J Biochem. 2006; 139(1):147-54. DOI: 10.1093/jb/mvj013. View

13.

Rieger M, Ferrari S, Kremer Hovinga J, Konetschny C, Herzog A, Koller L . Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA). Thromb Haemost. 2006; 95(2):212-20. DOI: 10.1160/TH05-08-0550. View

14.

Vaziri-Sani F, Holmberg L, Sjoholm A, Kristoffersson A, Manea M, Fremeaux-Bacchi V . Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome. Kidney Int. 2006; 69(6):981-8. DOI: 10.1038/sj.ki.5000155. View

15.

Peyvandi F, Lavoretano S, Palla R, Valsecchi C, Merati G, De Cristofaro R . Mechanisms of the interaction between two ADAMTS13 gene mutations leading to severe deficiency of enzymatic activity. Hum Mutat. 2006; 27(4):330-6. DOI: 10.1002/humu.20267. View

16.

Loirat C, Veyradier A, Girma J, Ribba A, Meyer D . Thrombotic thrombocytopenic purpura associated with von Willebrand factor-cleaving protease (ADAMTS13) deficiency in children. Semin Thromb Hemost. 2006; 32(2):90-7. DOI: 10.1055/s-2006-939764. View

17.

Tsai H, Raoufi M, Zhou W, Guinto E, Grafos N, Ranzurmal S . ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura. Thromb Haemost. 2006; 95(5):886-92. PMC: 2603189. View

18.

Feys H, Liu F, Dong N, Pareyn I, Vauterin S, Vandeputte N . ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences. J Thromb Haemost. 2006; 4(5):955-62. DOI: 10.1111/j.1538-7836.2006.01833.x. View

19.

Kremer Hovinga J, Mottini M, Lammle B . Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods. J Thromb Haemost. 2006; 4(5):1146-8. DOI: 10.1111/j.1538-7836.2006.01904.x. View

20.

Stahl A, Svensson M, Morgelin M, Svanborg C, Tarr P, Mooney J . Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets through TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome. Blood. 2006; 108(1):167-76. PMC: 1895830. DOI: 10.1182/blood-2005-08-3219. View